Repercusiones agudas en la Fevi por el uso de trastuzumab en pacientes con cáncer de mama HER2 positivo atendidas en el servicio de oncología del Hospital Teodoro Maldonado Carbo durante periodo enero 2016 a junio 2019.

Abstract

Introduction: Breast cancer is an important health issue since it is one of the main causes of death in women. In the last decades there has been an increase in the survival rate due to early detection programs and treatment improvement. Objective: Evaluate the relationship between the use of Trastuzumab and the reduction in left ventricular ejection fraction (LVEF) in patients with HER2 Positive Breast Cancer at Hospital Teodoro Maldonado Carbo during the period from January 2016 to June 2019. Materials and methods: An observational, retrospective and analytical study in which secondary data is collected from the medical records of patients treated at the Oncology area of the Teodoro Maldonado Carbo Hospital from January 1, 2016 to June 30, 2019. The analysis of the obtained data from the HTMC AS-400 database will be performed with Excel 2013 program, SPSS v25.0 Conclusion: The study population was 150 breast cancer HER2 + treated at the Teodoro Maldonado Carbo Hospital. Treatment with Trastuzumab significantly decreased LVEF in this study (p= 0.000) as well as the use of radiotherapy during treatment with Trastuzumab (p= 0.000). KEYWORDS: